3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Lymphoma
2
Stomatitis
1
Neuroendocrine Tumors
1
Neoplasms
1
Mucositis
1
Mouth Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Radiotherapy
6
Fibroblast Growth Factor 7
4
Injections
3
Drug Therapy
3
Cisplatin
3
Water
2
Propolis
2
Mouthwashes
2
Morphine
2
Methotrexate
2
Melphalan
2
Low-Level Light Therapy
2
Interleukin 1 Receptor Antagonist Protein
2
Gabapentin
2
Cryotherapy
2
peppermint oil
1
pegaspargase
1
oxycodone-acetaminophen
1
nelarabine
1
kang-lai-te
1
glucarpidase
1
fludarabine phosphate
1
fish oil triglycerides
1
cyclohexaneacetic acid
1
calcium phosphate
1
brilacidin
1
anise oil
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
acetaminophen, hydrocodone drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mucositis
×
RRx-001
×
Clear all
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts